Bacon P A, Tribe C R, Mackenzie J C, Verrier-Jones J, Cumming R H, Amer B
Q J Med. 1976 Oct;45(180):661-84.
Fourteen patients who developed persistent proteinuria while on penicillamine for rheumatoid arthritis, were collected over a period of one year. Eleven patients had a frank nephrotic syndrome and three had a lesser degree of proteinuria but no oedema. The patients had received penicillamine (mean daily dose 1015 mg) for less than one year (mean 7-5 months) when the nephropathy was detected. Clinical investigations have been correlated with renal biopsy material. Light microscopy detected no abnormalities except for minimal hypercellularity in a few patients. In markde contrast, the electron-microscope revealed numerous electron-dense deposits (EED's) in the outer layer of the basement membrane. Immunofluorescence showed the presence of IgG and complement in the basement membrane, the intensity of which correlated with the number of EED's. The pathological picture was essentially the same in those patients with the nephrotic syndrome and those with proteinuria. In this series, we found no evidence that penicillamine induced renal damage by any other mechanism except immune complex deposition. Serological tests revealed little evidence for complement activation or consumption and platelet aggregation was the only positive direct test for circulating immune complexes. Renal biopsies were performed at differing intervals after the cessation of penicillamine therapy, which allowed assessment of the natural history of the pathological lesion and revealed a striking persistence of EDD's in some patients. Two patients showed an almost identical picture initially and at re-biopsy one year later. Persistent proteinuria was also a feature of the group as a whole. The pathological picture has similarities with that of idiopathic membranous glomerulopathy. This study suggests that the use of penicillamine in rheumatoid arthritis may induce persistent renal damage.
在为期一年的时间里,收集了14例在服用青霉胺治疗类风湿关节炎期间出现持续性蛋白尿的患者。11例患者患有典型的肾病综合征,3例患者蛋白尿程度较轻但无水肿。在检测到肾病时,患者接受青霉胺治疗(平均每日剂量1015毫克)的时间不到一年(平均7.5个月)。临床检查结果与肾活检材料相关。光镜检查除少数患者有轻微细胞增多外未发现异常。与之形成鲜明对比的是,电镜显示基底膜外层有大量电子致密沉积物(EED)。免疫荧光显示基底膜中有IgG和补体存在,其强度与EED的数量相关。肾病综合征患者和蛋白尿患者的病理表现基本相同。在本系列研究中,我们没有发现证据表明青霉胺除了通过免疫复合物沉积外还通过任何其他机制导致肾损害。血清学检查几乎没有发现补体激活或消耗的证据,血小板聚集是循环免疫复合物唯一阳性的直接检测指标。在停止青霉胺治疗后的不同时间进行了肾活检,这有助于评估病理病变的自然病程,并发现一些患者的EED持续存在。两名患者最初及一年后再次活检时表现几乎相同。持续性蛋白尿也是整个研究组的一个特征。病理表现与特发性膜性肾小球病相似。本研究提示,类风湿关节炎患者使用青霉胺可能会导致持续性肾损害。